Latest news with #IL-6
Business Insider
04-07-2025
- Health
- Business Insider
Just 1 cup of black beans curbs inflammation in your body. Here are 4 science-backed recipes to boost your health.
Beans, beans, the magical fruit. The more you eat, the more you … can cut down on dangerous, chronic low-grade inflammation. Researchers at Illinois Institute of Technology recently discovered just how much black beans can help lower inflammation in a remarkable trial. They gave roughly two dozen people with prediabetes a three-month supply of canned beans. The directions were simple: incorporate one cup of black beans into your diet, every single day for 12 weeks. (In a control group, participants ate white rice instead). Some people mixed their beans into soups, others topped their salads with black beans. Each person in the bean-eating group just had to ensure they were eating a cup per day. It's something that people living in the longevity Blue Zones around the world already do automatically, through force of habit. With this study, there's fresh evidence that their technique can help anybody who is at risk of developing chronic diseases improve their health and longevity. Black beans owe their dark, deep hue to plant chemicals that may also help fend off inflammation In this small study, eating black beans had a big impact on people's levels of a protein called interleukin-6 (IL-6) which is a key marker of inflammation. During the course of the study, black bean eaters reduced their average IL-6 levels from 2.57 picograms per milliliter to 1.88, a significant decrease. Lead researcher Indika Edirisinghe, a professor of food science and nutrition at IIT, says he suspects a big part of the reason why black beans are so great at lowering chronic, low-grade inflammation has to do with the chemicals that give them their rich, deep black coloring. "They have something called polyphenolic compounds," Edirisinghe told Business Insider. "The polyphenolic compounds are bioactive, and they have antioxidant and anti-inflammatory activity." Just in case participants were stumped on how to start incorporating more black beans into each day, they were given a lifeline: Edirisinghe and his team offered participants several mouthwatering bean recipes, including one for black bean brownies, a chicken and black bean chili, a bean "caviar" snack dip, and a colorful bean salad in a jar. "There's no rocket science," Edirisinghe said. "It's very simple, and there's a great opportunity here to become healthy." Here are 4 of the easy — and tasty — black bean recipes patients used during the study Taco salad in a jar Ingredients: 1 15-oz. can of black beans, rinsed and warmed up 1 lb. ground turkey 2 cups of frozen corn, thawed and warmed up 1 head of romaine, chopped 1 cup of shredded pepperjack cheese 1 cup of diced tomatoes 1 tbsp. taco seasoning 2 tbsp. extra virgin olive oil Salt Directions: In a large skillet, heat the olive oil over medium-high heat Add the turkey and season with taco seasoning and salt Cook the turkey, breaking it up with a spoon or spatula, until it is golden and cooked through, about eight to 10 minutes. Then set it aside for five minutes to let it cool. Using six mason jars, layer the turkey, then black beans, corn, romaine, cheese, and tomatoes Refrigerate until ready to eat. (Makes a great lunch!) Black bean brownies 1 15-oz. can of black beans, drained and rinsed 1/2 cup of oats 1/2 tsp. baking powder 2 tbsp. cacao powder 1/4 tsp. salt 1/2 cup maple syrup 1/4 cup coconut oil 2 tsp. vanilla extract 1/3 cup chocolate chips, plus extra for topping Directions: Preheat your oven to 350F Combine all the ingredients except the chocolate chips in a food processor, and blend until very smooth. (If you don't have a food processor, a blender can work, but the consistency won't be as smooth.) Stir in the chips Pour into a well greased 8x8 pan Sprinkle extra chips on top, if you like Cook brownies for 15 to 18 minutes Let cool for at least 10 minutes before cutting If they still look somewhat undercooked, put them in the fridge for an hour to firm up Chicken, quinoa, and black bean chili verde Ingredients: 1 15-oz. can of black beans, rinsed 1 rotisserie chicken, shredded 6 cups of chicken broth 1 cup of quinoa 1 16-oz. jar of salsa verde 3 cloves of garlic, minced 1 large onion, diced 1 tbsp. of canola oil 1 tbsp. of ground cumin Salt Sour cream and cilantro, for serving Directions: In a large pot over medium heat, heat up the oil Cook the onion and garlic until tender, about six minutes Add the cumin, and season with salt Add the beans, chicken, and salsa verde and stir until combined Add 5 cups of the chicken broth and quinoa and bring to a boil Reduce the heat and let it simmer until the quinoa is tender, about 20 minutes If the quinoa absorbs most of the liquid, add the extra cup of chicken broth Serve with sour cream and cilantro Cowboy caviar Ingredients: 1 cup of black beans 1 cup of corn 1 cup of cherry tomatoes, quartered 1 small red onion, finely chopped 2 orange bell peppers, chopped 1 avocado, chopped 1 tsp. salt 1/2 tsp. cumin 1/3 cup of lime juice 1/3 cups of extra virgin olive oil 3 tbsp. of chopped fresh cilantro 1 tbsp. of hot sauce Tortilla chips for serving Directions: In a small bowl, combine the olive oil, lime juice, cilantro, hot sauce, cumin, and salt In a large bowl, combing the remaining ingredients, except the chips Pour the dressing from the small bowl into the large bowl and toss until well combined Serve it up with the chips
Hindustan Times
20-06-2025
- Health
- Hindustan Times
Do you floss your teeth properly? Doctor explains how it can lower heart disease risk
Flossing your teeth can help reduce the risk of heart disease. Dr Kunal Sood, an anesthesiology and interventional pain medicine physician, shared an Instagram post on June 19 in which he shared that research suggests that regular flossing can lower the risk of stroke and heart disease by reducing inflammation and preventing bacterial buildup in the mouth. Also read | Should you floss before or after brushing? Dentist shares what your ideal oral care routine should be In his caption, Dr Sood wrote, 'Can flossing reduce risk of heart disease? Share to help someone cut both gum and heart risk.' Saying how 'gums set off body-wide alarms', he said: 'Plaque trapped between teeth sparks gingivitis, letting Porphyromonas gingivalis and other microbes slip into the bloodstream. Those invaders crank up C-reactive protein (CRP) and IL-6 —the same inflammatory messengers that thicken arterial plaque and boost clotting risk.' Dr Sood added that 'flossing disrupts the oral-heart highway'. 'Adding floss to twice-daily brushing removes up to 80 percent of interdental plaque — far more than brushing alone. In a seven-year study of 40,000+ adults, flossing at least once a week was linked to: 22 percent lower ischemic-stroke risk, 44 percent lower cardio-embolic-stroke risk, and 12 percent lower atrial-fibrillation risk.' A post shared by Kunal Sood, MD (@doctorsoood) Explaining why frequency — and timing — matter, Dr Sood said, 'Every floss session breaks up biofilm before it inflames gum vessels. Even weekly flossing trims systemic inflammation, but daily use keeps the bacterial 'drip' shut off almost completely.' He also shared: 1. Floss daily (string, picks, or water-flosser); if that's tough, aim for several times per week — consistency beats perfection. 2. Brush twice daily and book professional cleanings every six months; scaling alone can drop CRP within weeks. 3. Spot warning signs — bleeding gums, chronic bad breath, looseness — then schedule a periodontal check-up. 4. Reinforce the win with cardio basics: quit smoking, manage blood sugar, move daily. The same habits that protect gums fortify arteries. Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
Yahoo
10-06-2025
- Business
- Yahoo
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
MRT-8102, a highly selective NEK7-directed molecular glue degrader (MGD) developed to treat inflammatory conditions linked to NLRP3, IL-1β, and IL-6 dysregulation, expands Monte Rosa's clinical I&I portfolio Potency, selectivity, and long-lasting pharmacodynamics of MRT-8102 observed in preclinical studies create potential for clinical differentiation from competitive approaches for inflammatory diseases MRT-8102 Phase 1 clinical results, including data on safety, pharmacokinetics, NEK7 protein degradation, and key downstream pharmacodynamic markers, expected in H1 2026 BOSTON, June 10, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory diseases driven by the NLRP3 inflammasome and IL-1β. The Company plans to initiate a Phase 1 study of MRT-8102 in the coming weeks and anticipates sharing initial results in H1 2026. 'The IND clearance of MRT-8102 is another important milestone in our quest to broadly establish MGDs as a modality in immunology and inflammatory (I&I) indications. MRT-8102, following on the heels of our VAV1-directed MGD MRT-6160, is our second IND specifically for I&I indications, and represents the only clinical-stage MGD that selectively targets NEK7, with potential to address multiple inflammatory diseases, including cardio-immunology, rheumatology, and respiratory indications,' said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics. 'We believe MRT-8102 could provide a highly differentiated clinical profile compared to IL-1 antibodies and NLRP3 inhibitors in development based on its potency, selectivity, and long-lasting pharmacodynamics. We look forward to initiating a Phase 1 healthy volunteer study in the coming weeks, with clinical results expected in H1 2026, including data on safety, pharmacokinetics, NEK7 protein degradation, and downstream pharmacodynamic markers. As part of the Phase 1 study, we plan to establish initial proof-of-concept (POC) for cardio-immunology indications by evaluating changes in C-reactive protein (CRP) and other key inflammatory markers in a cohort of subjects with high CRP levels.' Monte Rosa believes its preclinical studies support MRT-8102's potential to address multiple inflammatory diseases driven by the NLRP3 inflammasome, IL-1β and IL-6. MRT-8102 has demonstrated nanomolar-level degradation of NEK7 in vitro with no off-target activity observed, including related NEK family proteins. In non-human primates (NHPs), oral administration of MRT-8102 resulted in near-complete inhibition of downstream inflammatory markers in ex vivo stimulation assays, as well as improvements in pathological measures in inflammatory disease models. Furthermore, in a rabbit gout model, daily oral dosing of MRT-8102 was observed to reduce pathogenic effects, including a reduction in joint swelling and histopathology scores. Preclinical GLP toxicology studies suggest a considerable safety margin for MRT-8102, with a greater than 200-fold exposure margin over the projected human efficacious dose in both rats and NHPs. In addition to MRT-8102, Monte Rosa is also working to advance a second-generation NEK7 program with enhanced CNS penetration with an IND submission expected in 2026. Monte Rosa retains full worldwide rights to MRT-8102 and its second-generation CNS-optimized NEK7 MGDs. About MRT-8102MRT-8102 is a potent, highly selective, and orally bioavailable investigational molecular glue degrader (MGD) that targets NEK7 for the treatment of inflammatory diseases linked to NLRP3, IL-1β, and IL-6 dysregulation. NEK7 has been shown to be required for NLRP3 inflammasome assembly, activation and IL-1β release both in vitro and in vivo. Aberrant NLRP3 inflammasome activation and the subsequent release of active IL-1β and interleukin-18 (IL-18) has been implicated in multiple inflammatory disorders, including cardiovascular disease, gout, osteoarthritis, neurologic disorders including Parkinson's disease and Alzheimer's disease, and metabolic disorders. In a non-human primate model, MRT-8102 was shown to potently, selectively, and durably degrade NEK7, and resulted in near-complete reductions of IL-1β and caspase-1 following ex vivo stimulation of whole blood. MRT-8102 has demonstrated a considerable safety margin (>200-fold exposure margin over projected human efficacious dose) in GLP toxicology studies. About Monte RosaMonte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa's QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry's leading pipeline of MGDs, which spans autoimmune and inflammatory diseases, oncology, and beyond. Monte Rosa has a global license agreement with Novartis to advance VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit Forward-Looking Statements This communication includes express and implied 'forward-looking statements,' including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and in some cases, can be identified by terms such as 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'objective,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'potential,' 'continue,' 'ongoing,' or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements contained herein include, but are not limited to, statements about our ability to grow our product pipeline, our ability to successfully complete research and further development and commercialization of our drug candidates in current or future indications, including the timing and results of our clinical trials and our ability to conduct and complete clinical trials, statements regarding our progress and speed of development of only-in-class and first-in-class molecular glue degrader therapeutics, statements around the Company's QuEEN™ discovery engine and the Company's view of its potential to rationally design MGDs with unprecedented selectivity, statements about the advancement and timeline of our preclinical and clinical programs, pipeline and the various products therein, including the ongoing development and progress of our NEK7-directed MGD, referred to as MRT-8102, our plans to initiate a Phase 1 study of MRT-8102 in the coming weeks and our expectations for the design and advancement of such Phase 1 study, including updates related to status, safety data, pharmacokinetics, NEK7 protein degradation, and key downstream pharmacodynamic markers and timing of data read-outs, including the planned readout in the first half of 2026, the Company's statements around the potential of MRT-8102 to address multiple inflammatory diseases driven by the NLRP3 inflammasome, IL-1β and IL-6, including cardio-immunology, rheumatology, and respiratory indications and the Company's belief that MRT-8102 could provide a highly differentiated clinical profile compared to IL-1 antibodies and NLRP3 inhibitors in development based on its potency, selectivity, and long-lasting pharmacodynamics, statements relating to MRT-8102's safety margin, as well as statements around the advancement and timeline of a second-generation NEK7 program and expectations to submit an IND to the FDA in 2026, the expected potential clinical benefit of any of our candidates, advancement and application of our platform, statements around our ability to capitalize on and potential benefits resulting from our research and translational insights, including announcements related to preclinical programs, statements regarding regulatory filings for our development programs, including the planned timing of such regulatory filings, such as IND applications, and potential review by regulatory authorities, as well as our expectations of success for our programs, among others. By their nature, these statements are subject to numerous risks and uncertainties, including those risks and uncertainties set forth in our most recent Annual Report on Form 10-K for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission on March 20, 2025, and any subsequent filings, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, performance, or events and circumstances described in the forward-looking statements will be achieved or occur. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, any future presentations, or otherwise, except as required by applicable law. Certain information contained in these materials and any statements made orally during any presentation of these materials that relate to the materials or are based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party studies, publications, surveys and other data to be reliable as of the date of these materials, we have not independently verified, and make no representations as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of our internal estimates or research and no reliance should be made on any information or statements made in these materials relating to or based on such internal estimates and research. InvestorsAndrew Funderburkir@ MediaCory Tromblee, Scient PRmedia@
Business News Wales
22-05-2025
- Health
- Business News Wales
New Research on Long-Covid Offers Hope for Patients Living with Condition
Dr Richard Webb A new clinical study from Cardiff Metropolitan University – in collaboration with Cwm Taf Morgannwg University Health Board (CTM UHB) – has highlighted new biomedical insights into long-Covid. The researchers say it could take existing studies one step closer to finding treatment for patients living with the condition. Long-Covid is a new condition which can affect people who have previously had the Covid-19 virus. Symptoms can include heart disease, muscle and joint pain, extreme tiredness, coughing, shortness of breath and memory difficulties. The clinical study – 'Seasonal variation in the associations between self-reported long-Covid symptoms and IL-6 signaling-related factors' – from Cardiff Met and CTM UHB included DNA and blood samples taken from 175 participants who had previously had the Covid-19 infection. The bloods taken measured levels of two proteins, 'Interleukin-6 (IL-6)' and 'Interleukin-6 Receptor (IL-6R)', while the DNA sample was used to detect which variant of IL-6R gene, known as 'IL-6R genotype', was present. IL-6 and IL-6R are made by the immune system to fight infection. IL-6R is the receptor that IL-6 attaches to – like a key fitting into a lock. This connection allows IL-6 to send signals that trigger an immune response. Craig Greenstock Craig Greenstock, 63, from Pontypridd took part in the study and was first admitted to hospital in December 2020 at the height of the pandemic after being diagnosed with CovidPneumonitis. He was previously fit and healthy. Craig went on to spend the next nine weeks in hospital, initially placed on a ventilator within the intensive care unit before being moved to various wards. He has since been diagnosed with long Covid and suffers with bouts of fatigue, breathlessness, brain fog, PTSD, night terrors and is being treated with three daily pumps for asthma related symptoms. A nodule was also discovered on Craig's lung following the infection. Craig said: 'I can safely say that when I was first admitted to hospital and what then developed was the scariest time of my life, both physically and mentally. 'I was extremely unwell for some time, with my family being given 24 hours for my condition to improve. My symptoms following the virus have been so significant it has resulted in me having to retire from work.' Participants were also asked to complete a questionnaire sharing their current long Covid symptoms at different times throughout the year to see if the change in seasons affected the condition, and to help get an accurate diagnosis. The purpose of the study – which was funded through The Cwm Taf Morgannwg University Health Board Collaborative Research Fund – was to better understand how these IL-6-related factors contribute to the risk of long-Covid and possibly initiate future strategies for using them as biomarkers predictive of risk. The results from the participants tested highlighted that long-Covid sufferers had elevated levels of IL-6 compared to those who had regained full health. The results also showed the risk of getting long-Covid appeared to be increased in patients with a particular type of IL-6R genotype, known as the 'AA' genotype. Dr Richard Webb, a Principal Lecturer in Biomedical Sciences in the Centre for Cardiovascular Research, Innovation and Development (CURIAD) at Cardiff Metropolitan University is leading on the study. He said: 'While interpretation is complicated by seasonal variations, the findings from the study point towards possible future use of IL-6 and IL-6R genotype as biomarkers predictive of long-Covid risk, which may bring advantages regarding the management and treatment of the illness.' Dr Ceri Lynch is a Consultant in Anaesthetics and Intensive Care Medicine and Critical Care Research Lead at Cwm Taf Morgannwg University Health Board and has worked alongside Cardiff Met on the long-Covid symptoms study. Dr Lynch said: 'This collaborative research between Cwm Taf Morgannwg and Cardiff Metropolitan University has shown some interesting and exciting findings with regard to the risk factors for developing long-Covid. We would like to continue this work, with the ultimate aim of identifying an effective drug treatment for the condition.' Craig added: 'I was very fortunate to have a positive attitude to life and fairly healthy, so strong enough, physically and mentally, to be able to fight the virus and ongoing recovery. 'I would be prepared to try any medicine that could improve my standard of life back to anywhere near where it was before I fell ill.' The team of researchers from Cardiff Met and CTM UHB will now look at how the findings from this study can be integrated into and support The Post-hospitalisation Covid-19 study (PHOSP-COVID) – which includes leading researchers and clinicians from across the UK working together to understand and improve long-term health outcomes for patients who have been in hospital with confirmed or suspected Covid-19.
Time of India
12-05-2025
- Health
- Time of India
Doctors say THIS mineral reduces inflammation
You must have heard the word inflammation a lot in the past few years, and how it can cause a host of health issues, including weight gain, heart disease, arthiritis etc. But is there a way to curtail it? Let's find out more: What exactly is inflammation? Inflammation is the body's natural response to injury or infection. While short-term inflammation helps heal wounds and is not a cause of concern (say like a fever), however if chronic, inflammation can cause a host of health issues, as mentioned earlier. However, do you know that there is one mineral that can reduce inflammation naturally? And that mineral is magnesium . Let's take a look how... What is magnesium? Magnesium is a key mineral found in foods like nuts, seeds, leafy greens, and whole grains. Magnesium helps regulate the immune system and inflammation. When magnesium levels are low, the body tends to have more inflammation, which can lead to health issues. How does it reduce inflammation? One way magnesium reduces inflammation is by lowering the levels of proteins called cytokines. In layman language, cytokines are like messengers that tell the immune system to start or stop inflammation. Some cytokines cause inflammation, and when they are too high, it leads to chronic inflammation . Doctors say that magnesium decreases the production of inflammatory cytokines such as TNF-alpha and IL-6. It does this by blocking a key pathway inside cells called NF-κB (Nuclear Factor kappa B). NF-κB controls the activity of many genes involved in inflammation. Magnesium stops NF-κB from becoming too active, which in turn calms the immune response. Natural Calcium Blocker Magnesium also helps reduce inflammation by balancing calcium levels in the body. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Invest $200 in Amazon without buying stocks to earn a second salary Marketsall Sign Up Undo While Calcium is needed for many body functions, too many of calcium cells can cause cause inflammation and damage. Magnesium acts like a natural calcium blocker, preventing excess calcium from entering cells and triggering inflammation. Lowers inflammatory markers Inflammatory markers like C-reactive protein (CRP) and fibrinogen are substances in the blood that increase during inflammation. Research shows that magnesium supplements can significantly reduce these markers, indicating a lower level of inflammation in the body. Magnesium helps the immune system Magnesium supports the immune system by regulating how it responds to threats. Low magnesium levels can cause an overactive immune response, leading to high inflammation. By increasing magnesium levels, the immune system becomes better balanced, reducing the risk of chronic inflammation and related illnesses. Now, let's take a look at foods that are high in magnesium: Leafy green vegetables Nuts and seeds Legumes Whole grains Fruits Fish Dark chocolate Get the latest lifestyle updates on Times of India, along with Mother's Day wishes , messages , and quotes !
